Now, the biotech company is scrambling to supply enough of the drug known as remdesivir to fuel clinical studies, compassionate use and expanded access programs, and emergency use for patients with Covid-19, the respiratory illness caused by the new form of coronavirus.The Institute for Clinical and Economic Review, which examines the value of drugs, put a fair price for the coronavirus treatment at $4,500, RBC Capital Markets analyst Brian Abrahams said in a report.